Adding belzutifan after kidney-cancer surgery delayed relapse, not death
LITESPARK-022 cut the risk of recurrence by 28% when belzutifan was added to pembrolizumab after surgery. Survival was no different, and severe side effects nearly doubled.
In BRCA-normal ovarian cancer, the gain in KEYLYNK-001 tracks olaparib, not pembrolizumab
Adding pembrolizumab plus maintenance olaparib to first-line chemotherapy improved progression-free survival — but pembrolizumab added without olaparib did nothing at all.
Zanidatamab clears FDA for first-line HER2-positive gastro-oesophageal cancer
In HERIZON-GEA-01, zanidatamab plus chemotherapy raised median progression-free survival to 12.4 months from 8.1 with trastuzumab. A clear survival gain came only when tislelizumab was added.
An mRNA cancer vaccine just won a late-stage trial. Here is what that actually means.
Moderna and Merck's personalized vaccine slowed melanoma's return when added to Keytruda. It is the first mRNA cancer vaccine to succeed at scale — and the first real test of a decade-old idea.
Ivonescimab plus chemo extended survival in EGFR lung cancer after TKI failure
The final HARMONi-A analysis reports a 2.7-month gain in median overall survival — 16.8 versus 14.1 months — for the PD-1/VEGF bispecific added to chemotherapy in a China-only phase 3 trial.
Drug pair beat cisplatin chemo before bladder surgery in a head-to-head trial
In KEYNOTE-B15/EV-304, perioperative enfortumab vedotin plus pembrolizumab lifted two-year event-free survival to 79.4% from 66.2% against standard cisplatin-based chemotherapy in patients fit for it.
Two drugs around surgery sharply cut relapse in muscle-invasive bladder cancer
In KEYNOTE-905/EV-303, adding enfortumab vedotin and pembrolizumab to surgery lifted two-year event-free survival to 74.7% from 39.4%. Serious side effects were common.
Drug conjugate plus immunotherapy delays advanced triple-negative breast cancer
In the phase 3 ASCENT-04 trial, sacituzumab govitecan with pembrolizumab lifted median progression-free survival to 11.2 months from 7.8 in PD-L1-positive disease. Survival data are immature.